Maternal characteristics of a cohort of pregnant women with HIV-1 infection;Características maternas en una cohorte de gestantes con infección por el VIH-1

Medicina Clinica

Volumn 127, Issue 4, 2006, Pages 121-125

  Solís Villamarzo, Isabel ^a   Muñoz Gálligo, Eloy ^b   Ramos Amador, José Tomás ^b   González Tomé, María Isabel ^b   Rojano Luque, Xavier ^c   Almeda Ortega, Jesús ^c  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c Centre d'Estudis Epidemiològics sobre la Sida a Catalunya CEESCAT Badalona   (Spain)

Author keywords

Antiretroviral drugs; HIV; Pregnancy

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; OBSERVATIONAL STUDY; PREGNANT WOMAN; PREVALENCE; PROGENY; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 33747002742     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090377     Document Type: Article

References (25)

1. Kuhn L, Steketee RW, Weedon J, Abrams EJ, Lambert G, Bamji M, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. J Infect Dis. 1999;179:52-8.
2. Pitt J, Brambilla D, Reichelderfer P, Landay A, McIntosh K, Burns D, et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis. 1997;175:567-75.
3. Simonds RJ, Steketee R, Nesheim S, Matheson P, Palumbo P, Alger L, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS. 1998;12:301-8.
4. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA. 1998;280:55-60.
5. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. N Engl J Med. 1999;340:977-87.
6. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-80.
7. Cooper ER, Nugent RP, Díaz C, Pitt J, Hanson C, Kalish LA, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis. 1996;174:1207-11.
8. European Collaborative Study HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001;15:761-70.
9. Shapiro D, Tuomala R, Samelson R, Burchett S, Ciupak G, McNamara J, et al. Mother-to-child HIV transmission according to antiretroviral therapy, mode of delivery and viral load (PACTG 367) [resumen 114]. Actas de 9th Conference on Retroviruses and Oportunistic Infections; 2002, febrero 24-28; Seattle.
10. Centers for Disease Control and Prevention. Progress toward elimination of perinatal HIV infection-Michigan 1993-2000. MMWR Morb Mortal Wkly Rep. 2002;51:94-7.
11. Hill JB, Sheffield JS, Zeeman GG, Wendel GD. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstet Gynecol. 2001;98:909-11.
12. Blanche S, Tardieu M, Rustin P, Slama A, Barre T, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-9.
13. García PM, Beckerman K, Watts HW, Rodríguez E, Fox H, Tilson H, et al. Assesing the teratogenic potential of antiretroviral drugs: data from the Antiretroviral Pregnancy Registry (APR) [resumen I-1325]. Actas de 41th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001, diciembre 16-19; Chicago.
14. Coll O, Fiore S, Floridia M, Giaquinto C, Grosch-Wörner J, Giuliano M, et al. Pregnancy and HIV infection: a European Consensus on management. AIDS. 2002;16 Suppl 2:1-8.
15. Centers for Disease Control and Prevention. U.S. Public Health Service Task Force recommendations for use of antirretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 2002;51 (RR-18):1-38.
16. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41 (RR-17):1-19.
17. Scarlatti G. Paediatric HIV infection. Lancet. 1996;348:863-7.
18. Rogers MF, Shaffer N. Reducing the risk of maternal transmission of HIV by attacking the virus. N Engl J Med. 1999;341:441-2.
19. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet. 2000;355:2237-44.
20. Watts DH, Balasubramanian R, Maupin RT, Delke I, Dorenbaum A, Fiore S, et al (for the PACTG Team). Maternal toxicity and pregnancy complications in women receiving antiretroviral therapy. Am J Obstet Gynecol. 20004;190:506-16.
21. Justman JE, Benning L, Danoff A, Minkoff H, Levine A, Greenblatt RM, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298-302.
22. The European Collaborative Study and the Swiss Mother and Child HIV Cohort. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14:2913-20.
23. Lambert JS, Watts DH, Mofenson L, Stiem RER, Harris R, Bethel J, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. AIDS. 2000;14:1389-99.
24. Centers for Disease Control and Prevention. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep. 1995;44 (RR-7):1-15.
25. Secretaría del Plan Nacional sobre SIDA. Infección por VIH y embarazo. Recomendaciones del Consejo Asesor Clínico del Plan Nacional sobre SIDA n.° 6. Madrid: Ministerio de Sanidad y Consumo; 1996.